Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is designed to investigate the effects of a 12 week course of intravenous QAX576 6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients by 75% or greater when compared with baseline.
The primary endpoint in this study is the number of patients (responder) with a reduction of 75% or more in eosinophils per HPF (distal or proximal esophagus) from baseline to week 13. [ Time Frame: 13 weeks ]
Secondary Outcome Measures :
To ascertain the effect of QAX576 in the frequency and severity of the symptoms of EoE. [ Time Frame: 34 weeks ]
To investigate the safety and tolerability of QAX576 in patients with EoE. [ Time Frame: 34 weeks ]
To establish the duration of clinical benefit after a 12 week course of therapy. [ Time Frame: 34 weeks ]
PK/PD relationship between blood levels of QAX576 and IL- 13 dependent gene expression in esophageal biopsies and soluble biomarkers, inflammatory and fibrotic markers within esophageal biopsies and activation markers expressed on peripheral [ Time Frame: 34 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Males and females aged 18-50 with symptomatic eosinophilic esophagitis
Female subjects must be women of non child bearing potential.
Elimination diet must have been tried.
Treatment for at least two months prior to enrollment on a protocol pump inhibitor .
Appropriate contraception must be used by males, (e.g., spermicidal gel plus condom)
Must be able to communicate well with the investigator, to understand and comply with the requirements of the study.
Understand and sign the written informed consent.
Have received corticosteroids within 3 months before starting the study for any symptoms.
Any other eosinophilic disorders.
History of clinical schistosomiasis, or having travelled within the preceding 6 months to an area with endemic schistosomiasis, including but not limited to Southeast and Southwest Asia, South America and Africa. Travel to these areas must not be planned for at least 6 months after the last dose.
Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing.
History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening.
Other protocol-defined inclusion/exclusion criteria may apply